Wells Fargo analyst Larry Biegelsen initiated coverage of GE HealthCare with an Overweight rating and $90 price target. The company is well positioned to capitalize on its opportunity in Alzheimer’s, the analyst tells investors in a research note. The firm expects $500M of incremental sales by 2027 for GE HealthCare, based on its analysis of the number of patients on Alzheimer’s drugs in the U.S., Europe and Japan. It believes the shares are attractively valued at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GEHC:
- GE HealthCare gets FDA okay for wireless monitoring solution Portrait Mobile
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- BofA starts ‘appropriately valued’ GE HealthCare at Neutral
- GE HealthCare initiated with a Neutral at BofA
- Mizuho healthcare analysts hold an analyst/industry conference call